Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Florenzo IannoneAngelo SemeraroGiorgio CarlinoLeonardo SantoRomano BucciLaura QuartaNicola MaruottiCarmelo ZuccaroAntonio MarsicoPaola Chiara Francesca FalapponeDaniela MazzottaFrancesco Paolo CantatoreMaurizio MuratoreGiovanni Lapadula

Published in: Clinical drug investigation (2019)

Our study revealed that the best predictor of certolizumab effectiveness in unselected patients with RA, PsA, or SpA was a biologic-naïve status and achievement of an early response within 3 months.

Keyphrases

rheumatoid arthritis
disease activity
ankylosing spondylitis
randomized controlled trial
systematic review
prostate cancer
interstitial lung disease
systemic lupus erythematosus
type diabetes
systemic sclerosis
glycemic control